( Open-label Extension of Phase II Study ...)Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting,Health

LEXINGTON, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced that results from the Company's Phase II EXPRESS trial for pagoclone in persistent developmental stuttering will be presented today at the 47th annual meeting of the New Clinical Drug Evaluation Unit (NCDEU), sponsored by National Institute for Mental Health (NIMH) and being held in Boca Raton, Florida. In addition, the presentation will include data from the first three months of open label treatment.

"The progress of the ongoing Phase II open-label phase has been extremely encouraging," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "Our investigators are reporting significant benefit for the vast majority of patients continuing in the open label phase and for several patients, these benefits have been life-changing."

"The results from the open-label extension study reveal that pagoclone is a promising medication for the long-term treatment of stuttering," stated Gerald A. Maguire, M.D., associate professor, department of psychiatry, University of California, Irvine School of Medicine. "As a researcher and a person who stutters, I am excited about the results. Although there is no cure for stuttering, this study suggests that pagoclone holds significant promise as a well-tolerated, effective pharmacologic treatment for stuttering and further studies are indicated."

The open label data demonstrated an improvement in nearly all efficacy measures compared to baseline that was at least double the magnitude seen in the initial 8 weeks of double-blind treatment. During the 8-week, double-blind portion of the study, patients who were randomized to placebo experienced a mean reduction in the percentage of syllables stuttered of 5%. After three months i
'"/>